Autoimmunity and viruses

Clinics in Liver Disease

Volumn 6, Issue 3, 2002, Pages 451-465

  Vogel, Arndt ^a   Manns, Michael P ^a   Strassburg, Christian P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN RECOGNITION; AUTOIMMUNE HEPATITIS; AUTOIMMUNITY; B LYMPHOCYTE ACTIVATION; BYSTANDER EFFECT; CROSS REACTION; DELTA AGENT HEPATITIS; HEPATITIS C; HUMAN; IMMUNOPATHOGENESIS; MOLECULAR MIMICRY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0036694473     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1089-3261(02)00024-7     Document Type: Review

References (99)

1. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 1996;93:2264-71.
2. Ohashi PS. T cell selection and autoimmunity: flexibility and tuning. Curr Opin Immunol 1996; 8:808-14.
3. Shevach EM. Regulatory T cells in autoimmmunity. Annu Rev Immunol 2000;18:423-49.
4. Strassburg C, Alex B, Zindy F, et al. Identification of cyclin A as a molecular target of antinuclear antibodies (ANA) in hepatic and non-hepatic diseases. J Hepatol 1996;25:859-66.
5. Strassburg CP, Jaeckel E, Manns MP. Anti-mitochondrial antibodies and other immunological tests in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:595-601.
6. Strassburg CP, Manns MP. Antinuclear antibody (ANA) patterns in hepatic and extrahepatic autoimmune disease. J Hepatol 1999;31:751.
7. Strassburg CP, Obermayer-Staub P, Alex B, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology 1996;11: 1582-92.
8. Strassburg CP, Obermayer-Staub P, Manns MP. Autoimmunity in liver diseases. Clin Rev Allergy Immunol 2000;18:127-39.
9. Matsumoto I, Staub A, Benoist C, et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme. Science 1999;286:1732-5.
10. Harris DP, Haynes L, Sayles PC, et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol 2000;1:475-82.
11. Mosmann T. Complexity or coherence? Cytokine secretion by B cells. Nat Immunol 2000;1: 465-6.
12. Mamula MJ. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev 1998;164:231-9.
13. Serreze DV, Chapmann HD, Varnum DS, et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD.Ig mu null mice. J Exp Med 1996;184:2049-53.]
14. Hemmer B, Stefanova I, Vergelli M, et al. Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol 1998;160:5807-14.
15. Wucherpfennig KW, Strominger JL. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 1995;80: 695-705.
16. James JA, Mamula MJ, Harley JB. Sequential autoantigenic determinants of the small nuclear ribonucleoprotein Sm D shared by human lupus autoantibodies and MRL 1pr/1pr antibodies. Clin Exp Immunol 1994;98:419-26.
17. Bockenstedt LK, Gee RJ, Mamula MJ. Self-peptides in the initiation of lupus autoimmunity. J Immunol 1995;154:3516-24.
18. Topfer F, Gordon T, McCluskey J. Intra- and intermolecular spreading of autoimmunity involving the nuclear self-antigens La (SS-B) and Ro (SS-A). Proc Natl Acad Sci USA 1995;92:875-9.
19. Ohashi PS. Oehen S Buerki K, et al: Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65:305-17.
20. von Herrath MG, Dockter J, Oldstone MB. How virus induces a rapid or slow onset insulin-dependent diabetes mellitus in a transgenic model. Immunity 1994;1:231-42.
21. Streilien JW, Dana MR, Ksander BR. Immunity causing blindness: five different paths to herpes stromal keratitis. Immunol Today 1997;18:443-9.
22. Avery AC, Zhao ZS, Rodriguez A, et al. Resistance to herpes stromal keratitis conferred by an IgG2a-derived peptide. Nature 1995;376:431-4.
23. Zhao ZS, Granucci F, Yeh L, et al. Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 1998;279:1344-7.
24. Deshpande S, Zheng M, Lee S, et al. Bystander activation involving T lymphocytes in herpetic stromal keratitis. J Immunol 2001;167:2902-10.
25. Gangappa S, Deshpande SP, Rouse BT. Bystander activation of CD4+ T cells accounts for herpetic ocular lesions. Invest Ophthalmol Vis Sci 2000;41:453-9.
26. Dale JB, Beachey EH. Sequence of myosin-crossreactive epitopes of streptococcal M protein. J Exp Med 1986;164:1785-90.
27. Barrett-Connor E. Is insulin-dependent diabetes mellitus caused by coxsackie virus B infection? A review of the epidemiologic evidence. Rev Infect Dis 1985;7:207-15.
28. Szopa TM, Titchener PA, Portwood ND, et al. Diabetes mellitus due to viruses-some recent developments. Diabetologia 1993;36:687-95.
29. Tian J, Lehmann PV, Kaufman DL. T cell cross-reactivity between coxsackie virus and glutamate decarboxylase is associated with a murine diabetes susceptibility allele. J Exp Med 1994; 180:1979-84.
30. Yoon JW, Austin M, Onodera T, et al. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979;300:1173-9.
31. Kaufmann DL, Erlander MG, Clare-Salzler M, et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992;89:283-92.
32. Vreugdenhil GR, Geluk A, Ottenhoff TH, et al. Molecular mimicry in diabetes mellitus: the homologous domain in coxsackie B virus protein 2C and islet autoantigen GAD65 is highly conserved in the coxsackie B-like enteroviruses and binds to the diabetes associated HLA-DR3 molecule. Diabetologia 1998;41:40-6.
33. Atkinson MA, Bowman MA, Campbell L, et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94:2125-9.
34. Schloot NC, Roep BO, Wegmann DR, et al. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Diabetologia 1997;40:332-8.
35. Lonnrot M, Hyoty H, Knip M, et al. Antibody cross-reactivity induced by the homologous regions in glutamic acid decarboxylase (GAD65) and 2C protein of coxsackie virus B4. Childhood Diabetes in Finland Study Group. Clin Exp Immunol 1996;104:398-405.
36. Horwitz MS, Bradley LM, Harbertson J, et al. Diabetes induced by Coxsackie virus: initiation by bystander damage and not molecular mimicry. Nat Med 1998;4:781-5.
37. Benoist C, Mathis D. Autoimmunity provoked by infection: how good is the case for T cell epitope mimicry? Nat Immunol 2001;2:797-801.
38. Behar SM, Porcelli SA. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. Arthritis Rheum 1995;38:458-76.
39. Gangappa S, Deshpande SP, Rouse BT. Bystander activation of CD4(+) T cells can represent an exclusive means of immunopathology in a virus infection. Eur J Immunol 1999;29: 3674-82.
40. Sarvetnick N, Shizuru J, Liggitt D, et al. Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 1990;346:844-7.
41. Gianani R, Sarvetnick N. Viruses, cytokines, antigens, and autoimmunity. Proc Natl Acad Sci USA 1996;93:2257-9.
42. Gold DP. TCR V gene usage in autoimmunity. Curr Opin Immunol 1994;6:907-12.
43. Mitchell T, Kappler J, Marrack P. Bystander virus infection prolongs activated T cell survival. J Immunol 1999;162:4527-35.
44. Conrad B, Weissmahr RN, Boni J, et al. A human endogenous retroviral superantigen as candidate autoimmune gene in type I diabetes. Cell 1997;90:303-13.
45. Jaeckel E, Heringlake S, Berger D, et al. No evidence for association between IDDMK(1,2)22, a novel isolated retrovirus, and IDDM. Diabetes 1999;48:209-14.
46. Lower R, Tonjes RR, Boller K, et al. Development of insulin-dependent diabetes mellitus does not depend on specific expression of the human endogenous retrovirus HERV-K. Cell 1998;95: 4-11.
47. Murphy VJ, Harrison LC, Rudert WA, et al. Retroviral superantigens and type 1 diabetes mellitus. Cell 1998;95:9-11.
48. Manns MP, Strassburg CP. Autoimmune hepatitis: clinical challenges. Gastroenterology 2001; 120:1502-17.
49. Manns MP, Kruger M. Genetics in liver diseases. Gastroenterology 1994;106:1676-97.
50. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7.
51. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
52. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
53. Manns M, Gerken G, Kyriatsoulis A, et al. Characterization of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-4.
54. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. [see comments] Lancet 2000;355:1510-5.
55. Cianciara J, Laskus T. Development of transient autoimmune hepatitis during interferon treatment of chronic hepatitis B. Dig Dis Sci 1995;40:1842-4.
56. Rahaman SM, Chira P, Koff RS. Idiopathic autoimmune chronic hepatitis triggered by hepatitis A. Am J Gastroenterol 1994;89:106-8.
57. Robertson DA, Zhang SL, Guy EC, et al. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987;2:9-11.
58. Vento S, Cainelli F, Renzini C, et al. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997;350:1298-9.
59. Vento S, Garafano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337:1183-7.
60. Vento S, Guella L, Mirandola F, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995;346:608-9.
61. Manns MP, Jentzsch M, Mergener K, et al. Discordant manifestation of LKM-1 antibody positive autoimmune hepatitis in identical twins. Hepatology 1990;12:840.
62. Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991;338:277-80.
63. Todros L, Touscoz G, D'Urso N, et al. Hepatitis C virus-related chronic liver disease with autoantibodies to liver-kidney microsomes (LKM). Clinical characterization from idiopathic LKM-positive disorders. J Hepatol 1991;13:128-31.
64. McFarlane IG, Smith HM, Johnson PJ, et al. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet 1990;335:754-7.
65. Rowan BP, Smith A, Gleeson D, et al. Hepatitis C virus in autoimmune liver disease in the UK: aetiological agent or artefact? Gut 1994;35:542-6.
66. Lunel F, Abuaf N, Lionel F, et al. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. Hepatology 1992;16:630-6.
67. Michel G, Ritter A, Gerken G, et al. Anti-GOR and hepatitis C virus in autoimmune liver diseases. Lancet 1992;339:267-9.
68. Abuaf N, Lunel F, Giral P, et al. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol 1993;18:359-64.
69. Cacoub P, Lunel-Fabiani F, Huong Du LT. Polyarteritis nodosa and hepatitis C infection. Ann Int Med 1992;116:605-6.
70. Czaja AJ, Carpenter HA, Santrach PJ, et al. Evidence against hepatitis viruses as important causes of severe autoimmune hepatitis in the United States. J Hepatol 1993;18:342-52.
71. Reddy RK, Krawitt EL, Homberg JC, et al. Absence of anti-LKM1 in hepatitis C viral infection in the United States. J Viral Hepat 1995;2:175-9.
72. Haddad J, Deny P, Munz-Gotheil C, et al. Lymphocytic sialadenitis of Sjörgen's syndrome associated with chronic hepatitis c virus liver disease. Lancet 1992;339:321-3.
73. Pawlotsky JM, Ben Yahia M, Andre C, et al. Immunological disorders in C virus chronic active hepatitis: a prospective case-control study. Hepatology 1994;19:841-8.
74. Divano MC, Parodi A, Rebora A. Lichen planus, liver kidney microsomal (LKM1) antibodies and hepatitis C virus antibodies. Dermatology 1992;185:132-3.
75. Quint L, Deny P, Guillevin L, et al. Hepatitis C virus in patients with polyarteritis nodosa. Prevalence in 38 patients. Clin Exp Rheumatol 1991;9:253-7.
76. Johnson RJ, Gretch DR, Yamabe C, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 1993;18:465-70.
77. Pateron D, Hartman DJ, Vallee JCD, et al. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol 1992;992:244-5.
78. Tran A, Quaranta JF, Benzaken S, et al. High prevalence of thyroid antibodies in a prospective series of patients with chronic hepatitis C before interferon therapy. Hepatology 1993;18:253-7.
79. Agnello V, Chung RT, Kaplan L. A role of hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992;19:1490.
80. Cacoub P, Fabiani FL, Musset L, et al. Mixed cryoglobulinemia and hepatitis C virus. Am J Med 1994;96:124-32.
81. DeCastro M, Sanchez JJ, Herrera JF, et al. Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda. Hepatology 1993;17:551-7.
82. Fargion S, Peperno A, Cappellini MD, et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 1992;16:1322-6.
83. Mishiro S, Hoshi Y, Takeda K, et al. Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process. Lancet 1990;336:1400-3.
84. Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991;9:621-4.
85. Mackie FD, Peakman M, Ma Y, et al. Primary and secondary liver/kidney microsomal response following infection with hepatitis C virus. Gastroenterology 1994;106:1672-5.
86. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995;108: 1770-7.
87. Michitaka K, Durazzo M, Tillmann HL, et al. Analysis of hepatitis C virus genome in patients with autoimmune hepatitis type 2. Gastroenterology 1994;106:1603-10.
88. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 1994;19:13-8.
89. Durazzo M, Philipp T, Van Pelt FN, et al. Heterogeneity of microsomal autoantibodies (LKM) in chronic hepatitis C and D virus infection. Gastroenterology 1995;108:455-62.
90. Yamamoto AM, Cresteil D, Homberg JC, et al. Characterization of anti-liver-kidney microsome antobody (anti-LKM1) from hepatitis C virus-positive and -negative sera. Gastroenterology 1993;104:1762-7.
91. Duclos-Vallee JC, Hajoui O, Yamamoto AM, et al. Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal antibodies. Gastroenterology 1995;108:470-6.
92. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol 1973;15:331-44.
93. Crivelli O, Lavarini C, Chiaberge E, et al. Microsomal autoantibodies in chronic infection with HBsAg 3associated delta (delta) agent. Clin Exp Immunol 1983;54:232-8.
94. Buti M, Amengual MJ, Esteban R, et al. Serological profile of tissue autoantibodies during acute and chronic delta hepatitis. J Hepatol 1989;9:345-50.
95. Zauli D, Crespi C, Bianchi FB, et al. Autoimmunity in chronic liver disease caused by hepatitis delta virus. J Clin Pathol 1986;39:897-9.
96. Wesierska-Gadek J, Penner E, Hitchman E, et al. Antibodies to nuclear lamin C in chronic hepatitis delta virus infection. Hepatology 1990;12:1129-33.
97. Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet 1994;344:578-81.
98. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001;59:405-14.
99. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000;40:581-616.